Trials / Completed
CompletedNCT01289028
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
An Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the preliminary efficacy of nilotinib in pretreated patients (Imatinib, Sunitinib) with unresectable or metastatic gastrointestinal stromal tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nilotinib |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2011-02-03
- Last updated
- 2017-01-02
- Results posted
- 2016-11-01
Locations
19 sites across 2 countries: Germany, Italy
Source: ClinicalTrials.gov record NCT01289028. Inclusion in this directory is not an endorsement.